临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2015年
2期
120-122
,共3页
高血压合并高脂血症%阿托伐他汀%血压%血脂%超敏 C 反应蛋白
高血壓閤併高脂血癥%阿託伐他汀%血壓%血脂%超敏 C 反應蛋白
고혈압합병고지혈증%아탁벌타정%혈압%혈지%초민 C 반응단백
Hypertension patients with hyperlipidemia%Atorvastatin%Blood pressure%Blood lipids%High - sensitivity C - reactive protein
目的:分析探讨阿托伐他汀治疗高血压合并高脂血症患者疗效及其对血脂、超敏 C 反应蛋白(hs - CRP)的影响。方法将符合标准的高血压合并高脂血症96例患者按照单双号分为两组,每组各48例,即研究组和对照组。对照组应用氨氯地平片5 mg,每日1次。研究组在对照组的基础上加服阿托伐他汀10 mg,每日1次。两组疗程均为12周。分析两组治疗前后的收缩压(SBP)、舒张压(DBP)、血脂指标[(甘油三酯(TG)、血清胆固醇(TC)、脂蛋白胆固醇(LDL - C)和高密度脂蛋白胆固醇(HDL - C)]变化和 hs - CRP 变化。结果①两组治疗后血压均较治疗前显著降低,且研究组降低更明显,与对照组治疗后比较,差异具有统计学意义( P <0.05)。②对照组治疗前后血脂指标水平无显著改变,差异无统计学意义( P ﹥0.05)。研究组患者治疗后 TG、TC、LDL - C 水平较治疗前明显降低,HDL - C 水平较治疗前明显升高,差异均有统计学意义( P 均<0.05)。③研究组治疗后 hs - CRP 显著降低,与对照组比较,差异具有统计学意义( P <0.05)。④两组均未见明显不良反应。结论在氨氯地平的基础上加用阿托伐他汀治疗高血压合并高脂血症时,在降压、降脂方面效果更显著,hs - CRP 显著降低,安全性好,值得临床推广应用。
目的:分析探討阿託伐他汀治療高血壓閤併高脂血癥患者療效及其對血脂、超敏 C 反應蛋白(hs - CRP)的影響。方法將符閤標準的高血壓閤併高脂血癥96例患者按照單雙號分為兩組,每組各48例,即研究組和對照組。對照組應用氨氯地平片5 mg,每日1次。研究組在對照組的基礎上加服阿託伐他汀10 mg,每日1次。兩組療程均為12週。分析兩組治療前後的收縮壓(SBP)、舒張壓(DBP)、血脂指標[(甘油三酯(TG)、血清膽固醇(TC)、脂蛋白膽固醇(LDL - C)和高密度脂蛋白膽固醇(HDL - C)]變化和 hs - CRP 變化。結果①兩組治療後血壓均較治療前顯著降低,且研究組降低更明顯,與對照組治療後比較,差異具有統計學意義( P <0.05)。②對照組治療前後血脂指標水平無顯著改變,差異無統計學意義( P ﹥0.05)。研究組患者治療後 TG、TC、LDL - C 水平較治療前明顯降低,HDL - C 水平較治療前明顯升高,差異均有統計學意義( P 均<0.05)。③研究組治療後 hs - CRP 顯著降低,與對照組比較,差異具有統計學意義( P <0.05)。④兩組均未見明顯不良反應。結論在氨氯地平的基礎上加用阿託伐他汀治療高血壓閤併高脂血癥時,在降壓、降脂方麵效果更顯著,hs - CRP 顯著降低,安全性好,值得臨床推廣應用。
목적:분석탐토아탁벌타정치료고혈압합병고지혈증환자료효급기대혈지、초민 C 반응단백(hs - CRP)적영향。방법장부합표준적고혈압합병고지혈증96례환자안조단쌍호분위량조,매조각48례,즉연구조화대조조。대조조응용안록지평편5 mg,매일1차。연구조재대조조적기출상가복아탁벌타정10 mg,매일1차。량조료정균위12주。분석량조치료전후적수축압(SBP)、서장압(DBP)、혈지지표[(감유삼지(TG)、혈청담고순(TC)、지단백담고순(LDL - C)화고밀도지단백담고순(HDL - C)]변화화 hs - CRP 변화。결과①량조치료후혈압균교치료전현저강저,차연구조강저경명현,여대조조치료후비교,차이구유통계학의의( P <0.05)。②대조조치료전후혈지지표수평무현저개변,차이무통계학의의( P ﹥0.05)。연구조환자치료후 TG、TC、LDL - C 수평교치료전명현강저,HDL - C 수평교치료전명현승고,차이균유통계학의의( P 균<0.05)。③연구조치료후 hs - CRP 현저강저,여대조조비교,차이구유통계학의의( P <0.05)。④량조균미견명현불량반응。결론재안록지평적기출상가용아탁벌타정치료고혈압합병고지혈증시,재강압、강지방면효과경현저,hs - CRP 현저강저,안전성호,치득림상추엄응용。
Objective To investigate the effects of atorvastatin on blood lipids and high - sensitivity C - reactive protein(hs - CRP)in patients with hypertension and hyperlipidemia. Methods Ninety - six hypertension patients with hyperlipidemia were randomly divided into two groups,48 patients in each group. The control group was treated with 5 mg of amlodipine,once daily. In addition to the treatment of the control group,the study group was given 10 mg of atorvastatin,once daily. The treatment lasted 12 weeks. Systolic blood pressure,diastolic blood pres-sure,serum lipids and hs - CRP were analyzed before and after treatment. Results ① Blood pressure was significantly reduced after treatment, and it was more obvious in study group when compared with the control group( P < 0. 05). ② The levels of TG,TC,and LDL - C in the control group did not significantly change after treatment( P ﹥ 0. 05). The levels of TG,TC and LDL - C were significantly decreased and HDL - C level significantly increased after treatment in study group(all P < 0. 05). ③Hs - CRP level was significantly decreased after treatment in study group compared with the control group,the difference was statistically significant( P < 0. 05). ④No obvious adverse reactions were observed in both groups. Conclusion The combined use of amlodipine and atorvastatin was safe and can lower blood lipids,blood pressure and hs - CRP in pa-tients with hypertension and hyperlipidemia.